Clinical Trial: A single-arm, phase II, exploratory study of Culmerciclib in combination with letrozole and dual HER2 blockade with trastuzumab and pertuzumab as neoadjuvant therapy for HR-positive/HER2-positive breast cancer (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-arm, phase II, exploratory study of Culmerciclib in combination with letrozole and dual HER2 blockade with trastuzumab and pertuzumab as neoadjuvant therapy for HR-positive/HER2-positive breast cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131713

Registration Time: 2026/09/06

Type: Interventional study

Primary Sponsor: WeiHai Municipal Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=315643

Published by HT Digital Content Services with permission from Health Daily Digest....